Search

Displaying results 5331 - 5340 of 10000 in total
  1. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. … In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma.

  2. Drug

    Cefacetrile

    go.drugbank.com/drugs/DB01414
    InvestigationalVet approved

    A derivative of 7-aminocephalosporanic acid.

  3. Drug

    Implitapide

    go.drugbank.com/drugs/DB04852
    Investigational

    Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

  4. Drug

    Rebeccamycin

    go.drugbank.com/drugs/DB14729
    Investigational

    Rebeccamycin is a weak topoisomerase I inhibitor isolated from _Nocardia sp_.

  5. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    THC and CBD are converted from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation when unfertilized female cannabis flowers are activated either … isomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011].

  6. Drug

    Picric acid

    go.drugbank.com/drugs/DB03651
    Approved

    Used as antiseptic, astringent, and stimulant for epitheliazation.

    Categories: Indicators and Reagents
  7. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

    Categories: Dopa and Dopa Derivatives, foslevodopa and decarboxylase inhibitor
  8. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176]. … It is an anticholinergic drug and long-acting reversible carbamate cholinesterase inhibitor that binds directly and competitively to the agonist binding sites of muscurinic receptors.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

  10. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.